Return of Spasticity After Stopping THC–CBD Medicine Is Different From a Withdrawal Syndrome
Symptoms can return when an effective medicine is stopped without that return alone establishing drug withdrawal. A 2012 Sativex review distinguished recurrence of treated symptoms from the physiological or psychological dependence question.
The medicine treated an underlying condition
The review concerned a specified THC–CBD preparation used for multiple-sclerosis spasticity. The author reported that initial benefits were generally maintained and that symptoms often returned after stopping treatment. Recurrence may indicate loss of symptom control; it does not independently identify a new syndrome caused by cessation.
Withdrawal needs its own assessment
The author described cessation as generally safe in the clinical experience reviewed, without evidence of physiological or psychological dependence beyond symptom return. That is a bounded review conclusion, not proof that withdrawal is impossible with every cannabinoid product or regimen. Evaluating a cessation response requires attention to which symptoms were present before treatment and which emerged afterward.
Stable dosing and adverse events are separate observations
The review reported that dose escalation was not usually observed after early titration. It also described relatively frequent, usually mild-to-moderate adverse effects. Stable dosing does not establish absence of adverse effects, and tolerability does not independently determine dependence risk. These outcomes should not be treated as substitutes for one another.
Interpreting the evidence
The source is a historical clinical review, not an individualized discontinuation plan or a current legal-status statement. Its useful distinction is between recurrence of the treated disease, a cessation-related syndrome and other adverse effects.
Related reading: physiological histories and a broader dependence diagnosis.
Research reference
Wade D (2012). Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough? Expert review of neurotherapeutics. doi:10.1586/ern.12.12. Evidence basis: review abstract.
